In our previous communication (26th November 2008) related to the extra documents we received at the end of October, we raised the concern that the results of all the additional analysis conducted by both the DSU and PenTAG could not be replicated within the version of the executable model we had been given.

We would like to thank both the DSU and PenTAG for supplying us with the technical explanation of how they implemented the parameter changes to generate these new results. To test the reliability of model and derived analyses we re-entered all the data. We found no errors.

The one remaining concern we have is that under the terms of release of the model to Pfizer we were unable to test the validity of the assumptions regarding Sutent efficacy by comparing the modelled results with the Sutent empirical data. We believe that if we had been able to enter the Sutent data into the model we would have discovered that in a number of the modelled scenarios there was significant under/over estimation of efficacy with resultant under/over estimation of incremental cost effectiveness ratios.

Thank you again for providing us with the model and resulting analyses we look forward to discussing in the future how we can use these opportunities to gain a greater understanding of the modelling of our medicines.